NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/13/2022
Back to search
Official data from USPTO
PHAIM AIM ANTIGENIC IMMUNE MODULATION
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
PHAIM AIM ANTIGENIC IMMUNE MODULATION
ST13
US500000090770788Class
5, 10, 35, 44
Filing
90770788
Registration
6842815
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
20
Latest update
09/13/2022
Trademark type
Word
Nice classes
5, 10, 35, 44
Filing date
06/12/2021
Registration date
09/13/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/13/2022
Last transaction
09/13/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
London, GB
Examiner
GOODMAN, WENDY
Law office
L90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Phaim Pharma Ltd
Representatives
Joseph L. Morales THE MORALES LAW FIRM
Technical classification
Nice Classes
Class 5Class 10Class 35Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Vaccines; Chemical preparations for the diagnosis of diabetes; Pharmaceutical preparations for the prevention of diabetes; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for the prevention of diseases of the immune system; Pharmaceutical preparations for the prevention of disorders of the immune system; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the prevention of autoimmune diseases; Pharmaceutical preparations for the treatment of autoimmune disorders; Pharmaceutical preparations for the prevention of autoimmune disorders; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations; Chemical preparations for medical purposes
Class 10
Medical test kits for diabetes monitoring for home use; Testing instruments for medical diagnostic purposes; Blood glucose testing apparatus; Apparatus for carrying-out diagnostic tests for medical purposes; Diagnosticexaminationmonitoring equipment; Medical apparatus for testing the level of glucose in the blood; Medical apparatus and instruments; Medical diagnostic instruments; Medical testing instruments
Class 35
Advertising services relating to pharmaceuticals for the treatment of diabetes; Advertising services relating to pharmaceuticals; Advertisingmarketing and promotional services; Advertising; Compilation of statistical data for use in scientific research; Compilation of statistical data relating to medical research; Advertising services to promote public awareness of medical conditions; Advertising services related to immune disorders; Advertising services related to autoimmune diseases
Class 44
Diabetes screening services; Medical services in the field of diabetes; Providing information via the Internet in the field of diabetes; Medical screening; Health screening services; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical services for the diagnosis of conditions of the human body; Medical services; Medical diagnostic services; Medical services for the treatment of conditions of the human body; Medical testing services relating to the diagnosis and treatment of disease; Performing diagnosis of diseases; Medical information services provided via the Internet; Providing medical information; Medical analysis services for autoimmune disease diagnosis and prognosis
Publications
History of USPTO decisions and trademark events.
20 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
09/13/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/28/2022
PUBO
PUBLISHED FOR OPPOSITION
06/28/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/08/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/21/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
05/15/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/15/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
05/15/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/15/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/11/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/11/2022
ALIE
ASSIGNED TO LIE
03/09/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
03/07/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/03/2022
GNSL
LETTER OF SUSPENSION E-MAILED
03/03/2022
CNSL
SUSPENSION LETTER WRITTEN
03/03/2022
DOCK
ASSIGNED TO EXAMINER
03/03/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/01/2021
NWAP
NEW APPLICATION ENTERED
06/16/2021
Continuous trademark protection
Get notified about every new filing that threatens PHAIM AIM ANTIGENIC IMMUNE MODULATION or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.